Research Technologies

Roche is at the forefront when it comes to collaboration with biotechs at all development stages to drive the application of technology and modality platforms that have the potential to transform discovery as well as generate innovative medicines beyond the standard of care.

Partnering opportunities we are looking for:

Novel modalities and enabling technologies to expand the druggable target space
Targeted or intracellular delivery
Artificial intelligence for target and drug discovery
Genomic Medicine platforms

Example partnerships

Arrakis Therapeutics

research collaboration to discover and develop RNA-targeted small molecules against a broad set of targets across Roche's R&D areas

Orionis Biosciences

Collaboration to discover and develop novel small molecule medicines, including molecular glues, for challenging targets in major disease areas, including oncology and neurodegeneration.

Bicycle Therapeutics

research collaboration to discover and develop immunomodulatory bicyclic peptides for the treatment of cancer

Recursion

Research collaboration with Roche and Genentech to use machine learning and high content screening methods at scale to map complex biology in neuroscience and oncology

Nvidia

Partnership to accelerate R&D by using AI and computing technology to better understand disease biology and develop novel therapeutics

Sangamo

Global epigenetic regulation and capsid delivery license agreement to develop novel genomic medicines for neurodegenerative diseases

Shape Therapeutics

research collaboration to advance breakthrough AAV-based RNA editing technology for neuroscience and rare disease indications

Skyhawk

research collaboration to discover and develop small molecule RNA splicing modifiers for oncology and neurodegenerative diseases

Vividion Therapeutics

research collaboration to discover and develop compounds targeting novel E3 ligases and a range of oncology and immunology therapeutic targets based on Vividion's covalent chemistry